DCM
VRTX icon

Davidson Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Davidson Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,759
Closed -$3.97M – 116
2025
Q4 		$3.97M Sell
8,759
-36
-0.4% -$15.5K 0.86% 26
2025
Q3 		$3.44M Buy
8,795
+1,571
+22% +$657K 0.77% 36
2025
Q2 		$3.22M Sell
7,224
-196
-3% -$90.3K 0.77% 39
2025
Q1 		$3.6M Buy
7,420
+524
+8% +$244K 0.98% 10
2024
Q4 		$2.78M Buy
6,896
+365
+6% +$169K 0.73% 47
2024
Q3 		$3.04M Sell
6,531
-674
-9% -$324K 0.88% 37
2024
Q2 		$3.38M Buy
7,205
+1,383
+24% +$600K 1.04% 13
2024
Q1 		$2.43M Buy
5,822
+65
+1% +$27.5K 0.78% 42
2023
Q4 		$2.34M Buy
5,757
+786
+16% +$290K 0.85% 36
2023
Q3 		$1.73M Sell
4,971
-22
-0.4% -$7.69K 0.86% 24
2023
Q2 		$1.76M Buy
4,993
+31
+0.6% +$10.4K 0.88% 17
2023
Q1 		$1.56M Sell
4,962
-416
-8% -$125K 0.95% 14
2022
Q4 		$1.55M Sell
5,378
-19
-0.4% -$5.79K 1.07% 12
2022
Q3 		$1.56M Buy
5,397
+200
+4% +$57.5K 0.77% 10
2022
Q2 		$1.46M Sell
5,197
-1,413
-21% -$378K 0.69% 9
2022
Q1 		$1.73M Buy
6,610
+1,604
+32% +$381K 0.64% 9
2021
Q4 		$1.1M Sell
5,006
-1,228
-20% -$239K 0.6% 63
2021
Q3 		$1.13M Buy
6,234
+256
+4% +$50K 0.57% 63
2021
Q2 		$1.21M Buy
5,978
+848
+17% +$177K 0.58% 58
2021
Q1 		$1.1M Buy
5,130
+1,939
+61% +$426K 0.58% 57
2020
Q4 		$754K Buy
3,191
+117
+4% +$26.8K 0.42% 54
2020
Q3 		$836K Buy
3,074
+61
+2% +$16.8K 0.53% 28
2020
Q2 		$875K Buy
3,013
+141
+5% +$38.2K 0.77% 29
2020
Q1 		$683K Buy
+2,872
New +$659K 0.97% 24

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Davidson Capital Management's VRTX Position: Q1 2026 in Review

Davidson Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 8,759 shares — an estimated $3.97M sold.

Davidson Capital Management first reported a position in VRTX in Q1 2020 and held it in 24 quarters. The position peaked at $3.97M in Q4 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Davidson Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Davidson Capital Management sold 8,759 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.97M.
  • Davidson Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 24 quarters.
  • Davidson Capital Management's Vertex Pharmaceuticals position peaked at $3.97M in Q4 2025.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Davidson Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.